Clinical and quantitative coronary angiographic predictors of coronary restenosis A comparative analysis from the balloon-to-stent era by Mercado, Nestor et al.
Clinical and Quantitative Coronary
Angiographic Predictors of Coronary Restenosis
A Comparative Analysis From the Balloon-to-Stent Era
Nestor Mercado, MD, DSC,* Eric Boersma, PHD,* William Wijns, MD, PHD,†
Bernard J. Gersh, MB, CHB, DPHIL, FACC,‡ Carlos A. Morillo, MD,§ Vincent de Valk, PHD,\
Gerrit-Anne van Es, PHD,\ Diederick E. Grobbee, MD, PHD,¶ Patrick W. Serruys, MD, PHD, FACC*
Rotterdam and Utrecht, The Netherlands; Aalst, Belgium; Rochester, Minnesota; and Bucaramanga, Colombia
OBJECTIVES We sought to assess whether coronary stents have modified the predictive value of
demographic, clinical and quantitative coronary angiographic (QCA) predictors of coronary
restenosis.
BACKGROUND A systematic analysis in a large cohort of registries and randomized trials of the percutaneous
transluminal coronary angioplasty (PTCA) and stent era has never been performed.
METHODS A total of 9,120 treated lesions in 8,156 patients included in nine randomized trials and 10
registries, with baseline, post-procedural and six-month follow-up QCA analyses, were
included in this study. Predictors of restenosis were identified with univariate and multivariate
logistic regression analyses. Interaction terms were introduced in the regression equation to
evaluate whether the predictors of restenosis were common to both eras or specific for either
one of the revascularization techniques.
RESULTS The restenosis rate was 35% after PTCA and 19% after angioplasty with additional stenting.
In the univariate analysis, favorable predictors were previous coronary artery bypass graft
surgery (CABG), stent use, stent length and a large pre-procedural minimal lumen diameter
(pre-MLD); unfavorable predictors were weight, body mass index, diabetes mellitus,
multi-vessel disease, lesion length and a high residual post-procedural diameter stenosis
(post-DS). Predictors specific for the PTCA population were a large post-procedural MLD
(post-MLD) as favorable and a severe pre-procedural DS (pre-DS) as unfavorable. Favorable
predictors specific for the stent population were a large post-MLD and a large pre-procedural
reference diameter (pre-RD). In the multivariate analysis, the best model included the
following favorable predictors: stent use, a large post-MLD, previous CABG and the
interaction term between stent use and a large post-MLD; unfavorable predictors were lesion
length and diabetes mellitus.
CONCLUSIONS There are no major differences in demographic and clinical predictors of coronary restenosis
between PTCA and stent populations. In the modern (stent) era, a severe pre-DS is no longer
an unfavorable predictor of restenosis. Still important, but more so in the stent population, is
a large post-MLD (optimal result). Finally, a larger pre-RD became a favorable predictor
with the advent of stenting. (J Am Coll Cardiol 2001;38:645–52) © 2001 by the American
College of Cardiology
Coronary restenosis after a percutaneous intervention is a
complex multifactorial phenomenon. With the advent of
coronary stenting, constrictive vascular remodeling (a major
component of the process of restenosis) has been prevented,
and restenosis has decreased to a great extent. Nonetheless,
restenosis remains an important clinical problem that con-
tinues to exert a major negative impact on patients’ long-
term outcome after percutaneous coronary interventions.
Several demographic, clinical, quantitative coronary angio-
graphic (QCA) and intravascular ultrasound (IVUS)
variables have been described previously as predictors of
restenosis in either percutaneous transluminal coronary
angioplasty (PTCA) or stent populations (1–8).
From the mechanistic point of view, there is a clear
difference between restenosis after PTCA alone and PTCA
plus stenting. As assessed by IVUS studies, the prevailing
mechanism in restenosis after PTCA alone is arterial
remodeling, with late vessel contraction responsible for
.60% of late lumen loss (9), whereas accelerated intimal
hyperplasia predominantly causes in-stent restenosis (10).
Previous reports, which are hampered by their small
sample sizes, have analyzed a limited number of potential
predictors of restenosis in either the stent or PTCA popu-
lation analyzed separately. The aim of this study was to
assess to what extent the introduction of coronary stents has
modified the predictive value of previously identified demo-
graphic, clinical and QCA predictors of coronary restenosis
in the balloon era. We combined two patient populations:
patients treated with PTCA only (PTCA population) and
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patients who also had coronary stents implanted (stent
population).
METHODS
Patients were selected from 19 different studies: six random-
ized trials comparing the use of active medications aimed at
coronary restenosis prevention after PTCA alone or PTCA
plus stenting with placebo (Coronary Artery Restenosis
Prevention On Repeated Thromboxane A2-antagonism
[CARPORT] study [11], Multicenter European Research
trial with Cilazapril after Angioplasty to prevent Translu-
minal coronary Obstruction with Restenosis [MERCA-
TOR] [12], Prevention of Angioplasty Reocclusion with
Ketanserin [PARK] [13], Multicenter American Research
trial with Cilazapril after Angioplasty to prevent Translu-
minal coronary Obstruction with Restenosis [MARCA-
TOR] [14], FLuvastatin Angiographic REstenosis
[FLARE] [15] and TRAPidil In Stent [TRAPIST] [16]);
10 stent registries (BElgian NEtherlands STENT
[BENESTENT-2] pilot study [17], stent Primary Angio-
plasty in Myocardial Infarction [PAMI] pilot study [18],
West European Stent Trial [WEST-1] [19], WEST-2
[20], Wallstent native study [21], Registry for Optimal
beStent Evaluation [ROSE] [22], DUET [23], European
Antiplatelet Stent Investigation [EASI] [24], Study Of
PHosphorycholine coating On Stents [SOPHOS] [25] and
MAGIC 5-L [26]); and finally, three randomized trials
comparing PTCA plus coronary stenting with PTCA alone
(BENESTENT-1 [27], BENESTENT-2 [28] and stent
PAMI [29]).
These 19 studies were chosen because they are highly
representative of the randomized trials and registries of
PTCA and coronary stenting that have been performed in
the past decade, antedating the use of intracoronary brachy-
therapy. In eight studies, treatment of more than one lesion
per patient was allowed (CARPORT, MERCATOR,
PARK, MARCATOR, BENESTENT-2, FLARE, stent
PAMI, MAGIC 5-L); the remaining studies included only
patients with a single lesion. For patients with multilesion
PTCA or multilesion coronary stenting, all lesions were
analyzed, and each was considered independently.
Patients were included in this analysis if they had three
adequate angiograms—one immediately before the inter-
vention, one immediately after and one at six-month follow-
up. Patients with an unsuccessful procedure or with a lesion
in a saphenous vein graft were excluded.
Off-line analysis of angiographic outcomes was done
using identical and standardized methods of data acquisi-
tion and analysis and definitions of the variables in the same
core laboratory (Cardialysis, Rotterdam, The Netherlands)
using the Cardiovascular Angiography Analysis System II
(CAAS II) (Pie Medical, Maastricht, The Netherlands)
(30).
Definitions. Procedural success was defined as a post-
procedural diameter stenosis (post-DS) ,50% on visual
inspection in the early trials (CARPORT, MERCATOR,
PARK, MARCATOR and FLARE). Subsequently
(BENESTENT-1, BENESTENT-2 pilot, EASI,
BENESTENT-2, stent PAMI pilot, WEST-1, WEST-2,
Wallstent native, stent PAMI, ROSE, DUET, TRAPIST
and SOPHOS), procedural success was defined as ,50%
post-DS by on-line QCA and no occurrence of an in-
hospital major adverse cardiac event (death, acute myocar-
dial infarction, coronary artery bypass graft surgery [CABG]
or repeat PTCA), and finally, in the latest trial (MAGIC
5-L), procedural success was reset to ,20% post-DS by
on-line QCA in the absence of an in-hospital major adverse
cardiac event. Coronary restenosis was defined uniformly in
all but one randomized trial according to the binary criteria
with a cut-off point $50% DS at follow-up (31). In this
randomized trial (CARPORT), a noncategorical approach
was used, and restenosis was defined as a loss of $0.72 mm
in the MLD from post-PTCA to six-month follow-up. For
standardization purposes, we computed the binary resteno-
sis rate of this trial based on the DS on the follow-up
angiogram. The standard definitions for proximal and distal
segments of the right coronary artery, left anterior descend-
ing coronary artery (LAD) and left circumflex coronary
coronary artery have been described elsewhere (32). The
pre-procedural reference diameter (pre-RD) was obtained
by the interpolation method, and the lesion length was
defined by curvature analysis (33).
Statistical analysis. Statistical analysis was performed us-
ing the SAS version 8.0 software package (SAS Institute,
Cary, North Carolina). To test for differences in baseline
variables across the studies, the Kruskal-Wallis test (contin-
uous data) and the chi-square test (categorical data) were
applied. Univariate and multivariate logistic regression anal-
yses were used to evaluate the relationships between demo-
graphic data, clinical characteristics, stent use, QCA vari-
ables and the six-month outcome of angiographic
occurrence of restenosis, which was coded as a binary
variable according to the partial method. The stent length
was #15 mm (with a minimal length of 8 mm) in 68% of
patients with stents. In the remaining patients, the stent
length varied from 18 mm (DUET study) to 48 mm
(MAGIC 5-L study). For restenosis assessment, these two
different subsets of the stent population (#15 and .15 mm)
were compared with the PTCA population.
Abbreviations and Acronyms
CABG 5 coronary artery bypass graft surgery
CI 5 confidence interval
DS 5 diameter stenosis
IVUS 5 intravascular ultrasound
LAD 5 left anterior descending coronary artery
MLD 5 minimal lumen diameter
PTCA 5 percutaneous transluminal coronary angioplasty
OR 5 odds ratio
QCA 5 quantitative coronary angiography
RD 5 reference diameter
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Interaction terms between demographic data, clinical
characteristics, QCA variables and stent use were intro-
duced to evaluate the influence of coronary stents on the
predictors of coronary restenosis. To prevent associations by
chance, p , 0.001 was considered significant for these
interaction terms. All variables were entered into the mul-
tivariate model, irrespective of the results of the univariate
analysis (excluding the interaction terms in which the
specified level of significance was not reached). The final
multivariate model was constructed by backward deletion of
the least significant variables, while the Akaike criterion was
applied—that is, the applied threshold of significance de-
pended on the degrees of freedom (df) associated with the
variable at hand; if df 5 1, then p 5 0.157 (34). The
predictive accuracy of the final multivariate model was
evaluated using the C-index (35) and the goodness of fit of
the model was tested with the Hosmer-Lemeshow
goodness-of-fit test (36).
RESULTS
A total of 9,120 treated lesions in 8,156 patients were
considered for this study. Sixty-four percent of the patients
were treated with PTCA only (PTCA population: n 5
5,230; 6,110 lesions), and coronary stents were implanted in
36% of patients (stent population: n 5 2,926; 3,010 lesions).
The restenosis rate at six-month QCA follow-up was
35% after PTCA, compared with 19% after stenting. The
baseline characteristics of the PTCA and stent populations
are described in Table 1.
As might be expected (in such a heterogeneous popula-
tion), the demographic data and clinical characteristics were
significantly different across registries and trials. The pa-
tients’ median age increased from 57 years in the oldest trial
(CARPORT) to 62 years in the latest trial (MAGIC 5-L).
The percentage of diabetic patients varied from 5.8%
(MERCATOR) to 17% (Wallstent native); no temporal
trend was observed for this condition. The prevalence of
previous CABG varied from 1% (BENESTENT-1 and
stent PAMI pilot) to 5.6% (MARCATOR).
The pre- and post-procedural and six-month follow-up
QCA variables are described in Table 2. It is important to
note that the restenosis rate decreased from 38% in PARK
(1993, PTCA) to 12.8% in WEST-2 (1998, PTCA plus
stenting). This decrease in the restenosis rate was observed
despite a parallel increase in the length of treated lesions,
from a median of 5.8 mm in MERCATOR (1992, PTCA)
up to 14.3 mm in MAGIC 5-L (1999, PTCA plus







No. of patients 5,230 2,926 8,156
No. of treated lesions 6,110 3,010 9,120
Age (years) 59 (51, 65) 60 (52, 67) 59 (51, 66) ,0.0001
Men (%) 80.5 78 79 0.003
Height (cm) 172 (165, 178) 171 (165, 177) 172 (165, 178) 0.025
Weight (kg) 78 (70, 86) 78 (70, 87) 78 (70, 87) 0.732
History
Hypertension 33% 38% 35% ,0.0001
Diabetes mellitus 10% 12% 11% ,0.0001
MI 35% 29% 32% ,0.0001
PVD 5.3% 5.6% 5.4% 0.562
Angioplasty 6% 10% 8% ,0.0001
Bypass surgery 3.7% 2.7% 3.2% 0.010
Smoking status
Current 25% 29% 27% ,0.0001
Previous 60% 40% 50% ,0.0001
MVD 29% 28% 28.5% 0.089
Clinical diagnosis
CSA 84% 49% 66% ,0.0001
UA 8% 35% 21% ,0.0001
AMI 8% 16% 12% ,0.0001
Vessel treated
Proximal RCA 27% 34% 30.5% ,0.0001
Distal RCA 6.4% 6% 6.2% 0.493
Proximal LAD 20% 24% 22% 0.0003
Distal LAD 25% 20% 22.5% ,0.0001
Proximal LCx 6.2% 6.4% 6.3% 0.776
Distal LCx 15.4% 9.3% 12.3% ,0.0001
*Differences between the PTCA and stent populations. Data are presented as the median value (25th, 75th percentiles) or as
percentages.
AMI 5 acute myocardial infarction; CSA 5 chronic stable angina; LAD 5 left anterior descending coronary artery; LCx 5
left circumflex coronary artery; MI 5 myocardial infarction; MVD 5 multiple-vessel disease; PTCA 5 percutaneous
transluminal coronary angioplasty; PVD 5 peripheral vascular disease; RCA 5 right coronary artery; UA 5 unstable angina.
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stenting). The post-procedural minimal lumen diameter
(post-MLD) increased as well, with median values ranked
between 1.67 mm in PARK (1993, PTCA) to 2.89 mm in
EASI (1997, PTCA plus stenting).
By univariate analysis (Fig. 1), stent use clearly showed a
highly protective effect against restenosis (odds ratio [OR]
0.48, 95% confidence interval [CI] 0.43 to 0.53) when
compared with PTCA alone. Interestingly, the interaction
term for stent use was not significant when applied to
demographic and clinical variables. For post-MLD, pre-
procedural DS (pre-DS) and pre-RD, the interaction term
between stent use and the predictor was highly significant
(p 5 0.0009, p 5 0.0002 and p , 0.0001, respectively),
meaning they have different predictive values in the PTCA
and stent populations.
Favorable predictors common to the PTCA and stent
populations were previous CABG, stent use, stent length
,15 mm, stent length $15 mm and a large pre-procedural
MLD (pre-MLD); unfavorable predictors were weight,
body mass index, diabetes mellitus, multi-vessel disease,
lesion length and a high residual post-DS. Predictors
specific for the PTCA population were a large post-MLD
as favorable and a severe pre-DS as unfavorable. Favorable
predictors specific for the stent population were a large
post-MLD and a large pre-RD.
In the multivariate analysis, the model with the best predic-
tive accuracy and that best fit the entire population (Table 3)
was composed of the following favorable predictors: stent use
(OR 0.83, 95% CI 0.72 to 0.97), a large post-MLD (OR 0.53,
95% CI 0.46 to 0.61), previous CABG (OR 0.69, 95% CI 0.53
to 0.9) and the interaction term between stent use and a large
post-MLD (OR 0.34, 95% CI 0.31 to 0.39); unfavorable
predictors were lesion length (OR 1.05, 95% CI 1.04 to 1.06)
and diabetes mellitus (OR 1.33, 95% CI 1.16 to 1.54). The
Hosmer-Lemeshow goodness-of-fit test indicated that the
model fit well with the data (goodness-of-fit statistic 2.81, p 5
0.94).
The C-index for predictive accuracy initially demon-
strated a poor ability for demographic and clinical charac-
teristics to discriminate between patients who did and those
who did not develop coronary restenosis (C-index 5 0.51),
which subsequently improved slightly when the post-
procedural variables (mainly QCA) were added to the final
multivariate model (C-index 5 0.63).
DISCUSSION
In this study, several clinical and QCA predictors of
coronary restenosis were identified in a large number of
patients in two distinct populations. Significant demo-
graphic and clinical predictors of restenosis did not differ
between patients treated with PTCA alone and those with
stents. In contrast, three QCA variables were differentially
associated with restenosis. A large post-MLD was a favor-
able predictor in both the PTCA and stent populations, but
the protective effect was more marked in the stent popula-
tion. A severe pre-DS was an unfavorable predictor in the
PTCA population only, and a large pre-RD was a favorable
predictor in the stent population.
Clinical predictors. DIABETES MELLITUS. Patients with
diabetes mellitus have been repeatedly shown to have an
increased risk of developing restenosis, as compared with
nondiabetics (37,38). The mechanisms responsible for the
increased proclivity for restenosis in the diabetic patient are
not completely understood. In an IVUS analysis, it was
concluded that the main reason for increased restenosis in
diabetic patients was exaggerated intimal hyperplasia in
both stented and nonstented lesions (38). However, data
from Van Belle et al. (39) do not support this hypothesis,
but rather favor vessel remodeling (i.e., vessel constriction)
as the main mechanism.
Alterations in the expression of components of the
fibrinolytic system within the lesions of diabetic patients
may also be an important determinant of restenosis. Sobel et
al. (40) demonstrated, in a detailed immunohistochemical
analysis of coronary atherectomy samples, a disproportion-
ate elevation of concentrations of the prothrombotic plas-
minogen activator inhibitor type 1, which may induce
Table 2. Pre-Procedural, Post-Procedural and Six-Month Follow-Up Quantitative Coronary









No. of patients 5,230 2,926 8,156
No. of treated lesions 6,110 3,010 9,120
Pre-RD (mm) 2.65 (2.3, 3.02) 2.93 (2.64, 3.27) 2.75 (2.4, 3.12) ,0.0001
Lesion length (mm) 6.45 (5.03, 8.28) 8.94 (6.86, 12.38) 7.06 (5.4, 9.4) ,0.0001
Stent length (mm) — 15 (15, 18) 15 (15, 18) —
Pre-MLD (mm) 1 (0.81, 1.21) 0.98 (0.77, 1.18) 0.99 (0.79, 1.2) 0.0003
Post-MLD (mm) 1.77 (1.52, 2.05) 2.65 (2.38, 2.93) 2.02 (1.65, 2.5) ,0.0001
Pre-DS (%) 63 6 15.8 69 6 15 65 6 15.7 ,0.0001
Post-DS (%) 34 6 9.6 16.7 6 7.6 28 6 12 ,0.0001
Restenosis rate at 6-month
follow-up (%)
35 19 27 ,0.0001
Data are presented as the median value (25th, 75th percentiwles) or as the mean value 6 SD.
Pre- and post-DS 5 pre- and post-procedural diameter stenosis; pre- and post-MLD 5 pre- and post-procedural minimal
lumen diameter; pre-RD 5 pre-procedural reference diameter; PTCA 5 percutaneous transluminal coronary angioplasty.
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restenosis by clot-associated mitogens. More recently,
atherectomy specimens from restenotic lesions after PTCA
showed a reduced intimal hypercellular tissue content in
patients with diabetes (41). Collagen-rich sclerotic content
is increased, suggesting an accelerated fibrotic rather than a
proliferative response in diabetics with restenosis after
PTCA, putting into context again the fundamental impor-
tance of vessel remodeling in diabetics.
PREVIOUS CABG. In the present study, restenosis was less
likely to occur in the subgroup of patients with previous
CABG. Vein graft intervention was excluded from our
analysis. We can only speculate about possible mechanisms
leading to less restenosis in patients with previous CABG.
Some baseline characteristics differed between patients with
and those without previous CABG, such as a lower per-
centage of current smokers (14% vs. 26%) and a higher
proportion of patients with chronic stable angina (85% vs.
75%). However, these variables did not independently
predict restenosis by univariate analysis. The association is
weak, and residual confounding factors may have played a
role.
Figure 1. Univariate analysis of demographic, clinical and quantitative coronary angiography (QCA) predictors of coronary restenosis. When a common
odds ratio (OR) is presented, the interaction term between stent use and each of the variables was not significant (p $ 0.001), and then this is the OR (and
its corresponding 95% confidence interval [CI]) for the percutaneous transluminal coronary angioplasty (PTCA) and stent populations (solid circles). The
interaction term between stent use and each of the variables was significant (p , 0.001) if the PTCA (solid triangles) and stent (solid squares) populations
each had two ORs (with 95% CIs) presented. AMI 5 acute myocardial infarction; BMI 5 body mass index; CABG 5 coronary artery bypass graft surgery;
CSA 5 chronic stable angina; DM 5 diabetes mellitus; DS 5 diameter stenosis; HTA 5 hypertension; LAD 5 left anterior descending coronary artery;
LCx 5 left circumflex coronary artery; MI 5 myocardial infarction; MLD 5 minimal lumen diameter; MVD 5 multi-vessel disease; PVD 5 peripheral
vascular disease; RCA 5 right coronary artery; RD 5 reference diameter; UA 5 unstable angina.
Table 3. Multivariate Analysis: Clinical and Quantitative
Coronary Angiographic Predictors of Coronary Restenosis
Variable OR 95% CI p Value
Intercept coefficient 5 0.12 — — —
Stent use 0.83 0.72–0.97 0.0193
Lesion length 1.05 1.04–1.06 ,0.001
Post-MLD 0.53 0.46–0.61 ,0.001
Previous CABG 0.69 0.53–0.9 0.006
Diabetes mellitus 1.33 1.16–1.54 ,0.001
Stent use* post-MLD 0.34 0.31–0.39 0.002
*Interaction term between stent use and post-MLD. Hosmer and Lemeshow
goodness-of-fit statistic 5 2.81; p 5 0.94; C-index 5 0.63.
CABG 5 coronary artery bypass graft surgery; CI 5 confidence interval;
post-MLD 5 post-procedural minimal lumen diameter; OR 5 odds ratio.
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WEIGHT. Overweightness was positively associated with
restenosis by univariate, but not by multivariate analysis. It
may be argued that a potential relationship between obesity
and restenosis is mediated through increased lipid levels.
However, we found no association between total choles-
terol, cholesterol subfractions and restenosis after successful
PTCA by either a categorical or continuous approach (42).
CLINICAL DIAGNOSIS. We did not find the clinical diagno-
sis at the time of enrollment to be a predictor of restenosis
in either the PTCA or stent populations. However, in
patients treated with directional coronary atherectomy, clin-
ical instability was associated with signs of plaque inflam-
mation, which may promote restenosis (43).
Angiographic predictors. CORONARY STENTING. The
protective effect of coronary stenting against restenosis was
demonstrated unequivocally by two major randomized trials
(27,44). Further improvements in the technique of stent
deployment and new stent designs have also contributed to
decreasing the restenosis rate (45).
PRE-RD. The pre-RD is a predictor of restenosis in the stent
population, but not in the PTCA population. Because the
implantation of stainless-steel stents invariably results in
neointimal regrowth, .50% stenosis is more likely to occur
in vessels of small diameter. Supporting this concept,
Bauters et al. (3) showed that stenting in vessels with a small
RD was not associated with a greater lumen loss.
POST-MLD. The post-MLD clearly influences restenosis
development. The “bigger is better” paradigm proposed by
Kuntz et al. (46) means that for every millimeter of increase
in the post-MLD, there is an OR of 0.56 (95% CI 0.49 to
0.64) for restenosis in the PTCA population and an OR of
0.33 (95% CI 0.27 to 0.42) in the stent population. Our
findings indicate that the additional gain in post-MLD for
restenosis prevention is more relevant after stent deploy-
ment than after plain balloon angioplasty.
LESION LENGTH. Previous reports (5,47) have shown that
lesion length was positively related with restenosis in PTCA
alone and stented lesions. In these studies, lesion length was
dichotomized with cut-off values $6.8 mm for patients
treated with balloons and .15 mm for those treated with
stents. In this study, we used a continuous approach for
lesion length and for each millimeter of increase in length,
we found an OR of 1.04 (95% CI 1.03 to 1.05) for lesions
treated with both PTCA and stents.
STENT LENGTH. Our dichotomous approach for stent
lengths #15 mm and stent lengths .15 mm, each com-
pared to PTCA, indicated that the protective effect of
stenting against coronary restenosis is reduced by ;12%
when longer stents are used. Kobayashi et al. (48) similarly
demonstrated, in an analysis of 1,090 lesions in 725 patients,
that a progressively longer stented segment is associated
with an increased risk of restenosis, with six-month resten-
osis rates of 24%, 35% and 47% for stented segment lengths
#20, .20 to #35 and $35 mm, respectively. In a recent
pooled analysis of four Multi-Link stent trials (49), stent
length was found to be a significant predictor of restenosis
both by univariate and multivariate analyses, and for each
millimeter of increase in stent length, there was an or of
1.04 for restenosis development.
LOCATION OF TREATED LESION. The impact of the loca-
tion of the treated lesion on restenosis has been described in
previous PTCA (1) and stent (2) studies. Evidence is
conflicting, but most often, it is claimed that LAD lesions
are more prone to restenosis. In one study (1), an OR of 1.7
(95% CI 1.5 to 2.1) was found for proximal, as compared
with nonproximal LAD lesions treated with PTCA alone in
a sample of 2,500 patients. Another analysis of binary
restenosis at follow-up in 1,399 lesions reported an OR of
1.31 for stented lesions in the LAD (2). In these two
previous studies, a positive association was found, whereas
others noted that the location of the stented lesion had no
impact on restenosis after coronary stenting (3). After a
detailed analysis, our results indicate that there is no
evidence to support the idea that a given treatment location
plays a role in the restenotic process.
Study limitations. Short- and long-term clinical and an-
giographic outcomes after PTCA and stenting certainly
have improved over the past decade as a result of better stent
deployment strategies and more effective antithrombotic
regimens. Both balloon-expandable stents (Palmaz-Schatz
[PS]-153: 8.7%; heparin-coated PS-153: 33%; MULTI-
LINK: 9%; beStent: 4%; MULTI-LINK DUET: 5.2%;
Crossflex: 9.2%; and BiodivYsio: 6.7%) and self-expanding
stents (Magic Wallstent: 10.4%; Wallstent: 13.8%) were
used, and we did not stratify for the potential influence of
different stent types on restenosis.
New techniques, such as vascular brachytherapy (50) and
drug-eluting stents (51), have become available recently.
Patients treated with these modalities represent a distinctive
population in which the results of our analyses should not be
applied.
Conclusions. There are no major differences in demo-
graphic and clinical predictors of coronary restenosis be-
tween PTCA and stent populations. In the modern (stent)
era, a severe pre-DS is no longer an unfavorable predictor of
restenosis. Still important, but more so in the stent popu-
lation, is a large post-MLD (optimal result). Finally, a larger
pre-RD became a favorable predictor with the advent of
stenting.
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